Clinical Trial Detail

NCT ID NCT03473743
Title A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

transitional cell carcinoma

Therapies

Erdafitinib + JNJ-63723283

Age Groups: adult senior

No variant requirements are available.